Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity

维生素 D 加塞来昔布疗法刺激瘤内免疫反应

基本信息

  • 批准号:
    8390418
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-10-01 至 2014-09-30
  • 项目状态:
    已结题

项目摘要

Oral squamous cell carcinoma (OSCC) is an aggressive malignancy with a 5 year survival that has remained at 50% for the last 30 years. Immunotherapeutic approaches for OSCC patients may be alternative treatments. Unfortunately, OSCC patients have profound immune defects mediated by tumor-induced immune suppressor cells including tumor-mobilized CD34+ progenitor cells and Treg. Our past in vitro studies and our ongoing VA merit-review trial are showing that 1¿,25-dihydroxyvitamin D3 [1,25(OH)2D3] induces differentiation of immune suppressive CD34+ progenitor cells into immune stimulatory dendritic cells. However, we recently also showed that OSCC induce endothelial cells to become immune inhibitory by stimulating them to produce the immune suppressive mediator PGE2 which, in turn, induces their production of the suppressive mediator IL-6. Both PGE2 and IL-6 stimulate other suppressive cell types such as M2 macrophages and Treg cells. The hypothesis of this study is beneficial T-cell reactivity in OSCC tumors can be synergistically stimulated by blocking suppressor endothelial cells and their induction of other inhibitory cell populations while also maturing immune inhibitory CD34+ cells into antigen-presenting dendritic cells. To test this hypothesis, newly diagnosed OSCC patients will be administered the COX-2 inhibitor celecoxib and/or 1,25(OH)2D3 for the 3 week duration between cancer diagnosis and surgical treatment. The following aims will test the immunological and clinical effectiveness of the combination treatment: #1 To block the suppressive activity of endothelial cells and increase the levels of dendritic that are stimulatory to T-cell reactivity, thereby synergistically increasing intratumoral T-cell reactivity. These functional immune analyses will use OSCC tissues removed from untreated patients or patients treated with celecoxib and/or 1,25(OH)2D3. #2: To reduce development of OSCC recurrences by synergistically stimulating intratumoral T-cell reactivity with celecoxib to block suppressor endothelial cell activity and 1,25(OH)2D3 to mature CD34+ suppressor cells into T-cell stimulatory dendritic cells. The long-term application of these studies is to use treatments that block immune suppressor cells and enhance dendritic cell maturation together with T-cell activation vaccines targeting OSCC. The results of these studies will be applicable to other types of malignancies that induce immune suppressive cells, including lung and prostate cancer, which are increasing in prominence in the aging Veterans population.
口腔鳞状细胞癌(OSCC)是一种侵袭性恶性肿瘤,生存率为5年

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

M. Rita Young其他文献

M. Rita Young的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('M. Rita Young', 18)}}的其他基金

Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
维持 Th17 表型以防止癌前病变进展为癌症
  • 批准号:
    8774217
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
维持 Th17 表型以防止癌前病变进展为癌症
  • 批准号:
    8624540
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
维持 Th17 表型以防止癌前病变进展为癌症
  • 批准号:
    8433545
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
维生素 D 加塞来昔布疗法刺激瘤内免疫反应
  • 批准号:
    8586842
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
免疫疗法可预防口腔永久病变复发和口腔癌。
  • 批准号:
    7754439
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
维生素 D 加塞来昔布疗法刺激瘤内免疫反应
  • 批准号:
    7910667
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
维生素 D 加塞来昔布疗法刺激瘤内免疫反应
  • 批准号:
    8195963
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
免疫疗法可预防口腔永久病变复发和口腔癌。
  • 批准号:
    7574715
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
免疫疗法可预防口腔永久病变复发和口腔癌。
  • 批准号:
    7928678
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
免疫疗法可预防口腔永久病变复发和口腔癌。
  • 批准号:
    8010932
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Molecular mechanisms of carcinogenesis and symptoms associated with alcohol consumption
致癌的分子机制和饮酒相关症状
  • 批准号:
    23K05734
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The investigation of chronic alcohol consumption enhanced aging colon in elder mice and the mechanism of suppressed on aging colon tissues by sesame lignans continuous intake
长期饮酒促进老年小鼠结肠衰老的研究及持续摄入芝麻木脂素抑制结肠组织衰老的机制
  • 批准号:
    23K10904
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Internal Sources of Minority Stress and Alcohol Consumption
少数群体压力和饮酒的内部根源
  • 批准号:
    10742318
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Characterizing the Relationship Between Alcohol Consumption and Neuron-Derived Exosomal MicroRNA Cargo in an Adolescent-Young Adult Twin Cohort
青少年双胞胎队列中酒精消耗与神经元衍生的外泌体 MicroRNA 货物之间关系的表征
  • 批准号:
    10452928
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Endocrine regulation of alcohol consumption and fear learning
饮酒和恐惧学习的内分泌调节
  • 批准号:
    10483780
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
The impact of friends sharing different modalities of alcohol-related social media content on alcohol consumption: A longitudinal examination of changes in content shared by social networks over time
朋友分享不同形式的酒精相关社交媒体内容对饮酒的影响:对社交网络分享内容随时间变化的纵向研究
  • 批准号:
    10534428
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
  • 批准号:
    10339931
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
  • 批准号:
    10595096
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Chronic alcohol consumption results in elevated Autotaxin levels that suppress anti-tumor immunity
长期饮酒会导致自分泌运动因子水平升高,从而抑制抗肿瘤免疫力
  • 批准号:
    10370159
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Characterizing the Relationship Between Alcohol Consumption and Neuron-Derived Exosomal MicroRNA Cargo in an Adolescent-Young Adult Twin Cohort
青少年双胞胎队列中酒精消耗与神经元衍生的外泌体 MicroRNA 货物之间关系的表征
  • 批准号:
    10613564
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了